A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Running, not enrolling · Phase 3
Conditions studied: Familial Chylomicronemia Syndrome
In brief
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known as AKCEA -APOCIII-LRX) in participants with FCS previously treated with volanesorsen.
Key facts
- Study ID
- NCT05185843
- Run by
- Ionis Pharmaceuticals, Inc.
- People needed
- 24
- Starts
- 2022-02-25
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2025-12-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Diabetes/Lipid Management & Research Center — Huntington Beach, California, United States
- Excel Medical Clinical Trials, LLC — Boca Raton, Florida, United States
- University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND) — Ann Arbor, Michigan, United States
- University of Rochester School of Medicine — Rochester, New York, United States
- Centre for Heart Lung Innovation — Vancouver, British Columbia, Canada
- ARC Biosystems, Clinical Assessment Unit (CAU) — Vancouver, British Columbia, Canada
- St. Boniface General Hospital — Winnipeg, Manitoba, Canada
- Ecogene-21 — Chicoutimi, Quebec, Canada
- Clinique des Maladies Lipidiques de Quebec Inc. — Québec, Quebec, Canada
- Centre Hospitalier Universite de Sherbrooke (CHUS) — Sherbrooke, Quebec, Canada
- Karolinska University Hospital Huddinge — Stockholm, Sweden
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.